Workflow
Bionano Genomics(BNGO)
icon
Search documents
Bionano Genomics(BNGO) - 2023 Q1 - Earnings Call Transcript
2023-05-09 22:50
Bionano Genomics, Inc. (NASDAQ:BNGO) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants David Holmes - Investor Relations Erik Holmlin - Chief Executive Officer Chris Stewart - Chief Financial Officer Conference Call Participants Michael Okunewitch - Maxim Group Operator Good day and welcome to the Bionano Genomics First Quarter 2023 Earnings Conference Call. Today's conference is being recorded. All lines have been placed on mute to prevent any background noise. After the speakers ...
Bionano Genomics(BNGO) - 2023 Q1 - Quarterly Report
2023-05-08 16:00
A summary of the Company's stock option activity during the three months ended March 31, 2023 was as follows: | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------------|-------|-------------|-------|-------------------------------------------|-------|--------------------------------|--------------------------------------------|-------|---------------------------| | | | | | Shares of Stock under Stock Options | | WeightedAverage Exercise Price | WeightedAverage Remaining Cont ...
Bionano Genomics(BNGO) - 2022 Q4 - Earnings Call Transcript
2023-03-10 03:27
Bionano Genomics, Inc. (NASDAQ:BNGO) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants Amy Conrad - Investor Relations Erik Holmlin - Chief Executive Officer Chris Stewart - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Sung Ji Nam - Scotiabank Michael Okunewitch - Maxim Group Mark Massaro - BTIG Operator Good day and welcome to the Bionano Fourth Quarter and Full Year 2022 Earnings Conference Call. [Operator Instructions] Please be advised that ...
Bionano Genomics(BNGO) - 2022 Q4 - Annual Report
2023-03-08 16:00
• sales of our securities by us or our stockholders in the future; • trading volume of our securities; • changes in accounting practices; • ineffectiveness of our internal controls; • data breaches of our company, providers, vendors or customers; • regulatory or legal developments in the United States and other countries; • disputes or other developments relating to proprietary rights, including our ability to adequately protect our proprietary rights in our technologies; • significant lawsuits, including p ...
Bionano Genomics, Inc. (BNGO) Presents at Cowen 43rd Annual Healthcare Conference (Transcript)
2023-03-06 20:51
Bionano Genomics, Inc. (NASDAQ:BNGO) Cowen 43rd Annual Healthcare Conference March 6, 2023 1:30 PM ET Company Participants Erik Holmlin - Chief Executive Officer Conference Call Participants Tom Stevens - Life Science Tools & Diagnostic Team here at Cowen Tom Stevens All right, so should we get started?. So I’m Tom Stevens, Life Science Tools & Diagnostic Team here at Cowen. We have Erik Holmlin, take us through with his presentation and have agreed to name it, take it away. Erik Holmlin Great. Thank you ve ...
Bionano Genomics(BNGO) - 2022 Q3 - Earnings Call Transcript
2022-11-04 01:40
Bionano Genomics, Inc. (NASDAQ:BNGO) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Amy Conrad - Investor Relations Erik Holmlin - Chief Executive Officer Christopher Stewart - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Operator Good day, and welcome to the Bionano Genomics Third Quarter 2022 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Amy Conrad from ...
Bionano Genomics(BNGO) - 2022 Q3 - Quarterly Report
2022-11-02 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file numb ...
Bionano Genomics, Inc. (BNGO) Presents at H.C. Wainwright 24th Annual Global Investment Conference (Transcript)
2022-09-12 16:09
Bionano Genomics, Inc. (NASDAQ:BNGO) H.C. Wainwright 24th Annual Global Investment Conference September 12, 2022 7:00 AM ET Company Participants Erik Holmlin - President and Chief Executive Officer Conference Call Participants Trevor Levy - H.C. Wainwright Trevor Levy Good afternoon, everyone. And thank you for joining the H.C. Wainwright 24th Annual Global Investment Hybrid Conference. My name is Trevor Levy and I'm on the Corporate Access Team at HC Wainwright. While we are hybrid this year, we're confide ...
Bionano Genomics(BNGO) - 2022 Q2 - Earnings Call Transcript
2022-08-05 01:14
Bionano Genomics, Inc. (NASDAQ:BNGO) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Amy Conrad - Investor Relations Erik Holmlin - Chief Executive Officer Christopher Stewart - Chief Financial Officer Conference Call Participants Michael Okunewitch - Maxim Group Operator Good day and welcome to the Bionano Genomics’ Second Quarter 2022 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Amy Conrad from Inve ...
Bionano Genomics(BNGO) - 2022 Q2 - Quarterly Report
2022-08-03 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO | --- | --- | --- | --- | ...